Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome.

PMID 32746943 ↗2020Reported benefit

Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome.

MouseRadiationC57BL/6JJclFemaleIntraperitonealG-CSF 10 micrograms/kg/day and romiplostim 10 micrograms/kgStarted within 2 hours after total-body irradiation

Model: Lethal total-body X-irradiation at 7, 7.25 or 7.5 Gy

The clinical-dose G-CSF and romiplostim combination improved 30-day survival after lethal total-body irradiation and reduced haematopoietic apoptosis and oxidative stress.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome.

Evidence by therapy association

Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome.